IP Library › Granted Patent US 7,098,322
Granted Patent B2
US 7,098,322 · App. 10/757,745 · Granted Aug 29, 2006

CD40-interacting and TRAF-interacting proteins

Assignee: Vlaams Interuniversitair Instituut voor Biotechnologie VZW
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,098,322
App. No.
10/757,745
Granted
Aug 29, 2006
Kind
B2
Abstract

The present invention relates to novel proteins interacting with the cytoplasmic domain of CD40, which are useful in the treatment of CD40 and/or NF-κB related diseases. Surprisingly, these proteins do not show significant amino acid sequence identity with the members of tumor necrosis factor receptor associated factor (TRAF) family; and thus, offer the possibility to modulate the CD40 and/or NF-κB signaling pathway independently from interaction of TRAF with CD40.

Claims (3)

1. An isolated nucleic acid sequence encoding a protein, said protein characterized by an ability to form a complex with receptors of the Tumor Necrosis Factor (“TNF”) superfamily including the cytoplasmic domain of CD40 as determined by a yeast two-hybrid interaction assay or a co-immunoprecipitation assay, said protein comprising amino acids 54–140 of SEQ ID NO:2, or amino acids 54–362 of SEQ ID NO:2, or amino acids 54–273 of SEQ ID NO:2, or amino acids 54–236 of SEQ ID NO:2.

2. The isolated nucleic acid sequence of claim 1 comprising the nucleotide sequence encoding SEQ ID NO:2.

3. An isolated nucleic acid sequence encoding a protein comprising SEQ ID NO:6 or a fragment thereof comprising amino acids 2–245 of SEQ ID NO:6.

Priority Claims (1)
EP 98201392 · Apr 29, 1998 · regional
Continuity (3)
Division 0969786300 · Oct 27, 2000
Continuation PCTEP990302500 · Apr 28, 1999
Related Publication 20050101769A1 · May 12, 2005